NYSE: DSS
DSS, INC.CIK 0000771999 · SIC 2650 · Paperboard Containers & Boxes
Micro
Revenue $21M
Assets $68M
as of Sep 7, 2026
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (P 10-Q) is open in full — no account needed.
424B5
Filed Sep 4, 2026
Summary not yet generated.
10-Q
Filed Aug 14, 2026
· Period ending Jun 30, 2026
Summary not yet generated.
Partner
Trade DSS commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
8-K
Filed Jun 25, 2026
· Period ending Jun 23, 2026
Summary not yet generated.
10-Q
Filed May 15, 2026
· Period ending Mar 31, 2026
Summary not yet generated.
S-1/A
Filed Apr 24, 2026
Summary not yet generated.
S-1
Filed Apr 17, 2026
Summary not yet generated.
8-K
Filed Mar 31, 2026
· Period ending Mar 26, 2026
Summary not yet generated.
10-K
Filed Mar 31, 2026
· Period ending Dec 31, 2025
Summary not yet generated.
8-K
Filed Feb 5, 2026
· Period ending Feb 4, 2026
Summary not yet generated.
424B5
Filed Feb 5, 2026
Summary not yet generated.
10-K
Filed Mar 31, 2025
· Period ending Dec 31, 2024
Summary not yet generated.
10-K/A
Filed Oct 22, 2024
· Period ending Dec 31, 2023
Summary not yet generated.
424B5
Filed Jun 16, 2021
Summary not yet generated.
S-1/A
Filed Jan 14, 2021
Summary not yet generated.
S-1/A
Filed Jan 13, 2021
Summary not yet generated.
S-1
Filed Nov 4, 2020
Summary not yet generated.
424B3
Filed Jul 7, 2020
Summary not yet generated.
S-1
Filed May 21, 2020
Summary not yet generated.
424B3
Filed May 10, 2019
Summary not yet generated.
424B3
Filed Nov 8, 2013
Summary not yet generated.
10-Q/A
Filed Nov 14, 2011
· Period ending Jun 30, 2011
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 14, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Consolidated Statements of Operations (Unaudited)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Revenue: | ||||
| Printed products | 3,258,000 | 4,272,000 | 7,405,000 | 8,255,000 |
| Rental | 245,000 | 715,000 | 392,000 | 1,429,000 |
| Commercial lending | 6,000 | 9,000 | 12,000 | 29,000 |
| Commission | 92,000 | 282,000 | 115,000 | 503,000 |
| Biotechnology | 3,000 | 7,000 | 10,000 | 21,000 |
| Total revenue | 3,604,000 | 5,285,000 | 7,934,000 | 10,237,000 |
| Costs and expenses: | ||||
| Cost of revenue | 4,519,000 | 5,489,000 | 10,052,000 | 10,665,000 |
| Selling, general and administrative (including stock-based compensation) | 2,871,000 | 3,221,000 | 7,156,000 | 6,723,000 |
| Total costs and expenses | 7,390,000 | 8,710,000 | 17,208,000 | 17,388,000 |
| Operating loss | (3,786,000) | (3,425,000) | (9,274,000) | (7,151,000) |
| Other income (expense): | ||||
| Interest income | 2,000 | 13,000 | 3,000 | 17,000 |
| Interest income on note receivable, related party | 6,000 | 12,000 | 12,000 | 16,000 |
| Dividend income | 5,000 | - | 16,000 | - |
| Other income (expense) | 21,000 | 4,000 | 7,000 | 10,000 |
| Interest expense | (89,000) | (123,000) | (128,000) | (156,000) |
| Loss on equity method investment | (364,000) | (2,000) | (367,000) | (5,000) |
| (Loss) gain on investments | (830,000) | 1,557,000 | (1,531,000) | 627,000 |
| Impairment of intangible assets | - | (600,000) | - | (600,000) |
| Loss on sale of real estate | - | (43,000) | - | (727,000) |
| Loss from continuing operations before income taxes | (5,035,000) | (2,607,000) | (11,262,000) | (7,969,000) |
| Income tax benefit | - | - | - | 67,000 |
| Net loss | (5,035,000) | (2,607,000) | (11,262,000) | (7,902,000) |
| Loss from operations attributed to noncontrolling interest | 246,000 | 455,000 | 873,000 | 973,000 |
| Net loss attributable to DSS common stockholders | (4,789,000) | (2,152,000) | (10,389,000) | (6,929,000) |
| Loss per common share attributable to common stock holders | ||||
| Basic | (0.48) | (0.24) | (1.06) | (0.78) |
| Diluted | (0.48) | (0.24) | (1.06) | (0.78) |
| Shares used in computing loss per common share: | ||||
| Basic | 10,042,518 | 9,092,518 | 9,847,214 | 8,889,221 |
| Diluted | 10,042,518 | 9,092,518 | 9,847,214 | 8,889,221 |
Condensed Consolidated Balance Sheets (Unaudited)
| Description | As of June 30, 2026 | As of December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | 4,068,000 | 6,214,000 |
| Restricted cash | - | 100,000 |
| Accounts receivable, net | 1,286,000 | 2,254,000 |
| Inventory | 1,978,000 | 1,998,000 |
| Investments in trading securities | 1,090,000 | 2,694,000 |
| Current portion of notes receivable, net | 248,000 | 198,000 |
| Current portion of notes receivable related party | 231,000 | 238,000 |
| Prepaid expenses and other current assets | 467,000 | 649,000 |
| Total current assets | 9,368,000 | 14,345,000 |
| Property, plant and equipment, net | 4,610,000 | 4,819,000 |
| Investment in real estate, net | 16,357,000 | 16,637,000 |
| Investment, cost method | 500,000 | 500,000 |
| Investment, equity method | 11,994,000 | 113,000 |
| Investment in equity securities | 1,719,000 | 6,517,000 |
| Other assets | 65,000 | 71,000 |
| Right-of-use assets | 5,510,000 | 5,825,000 |
| Goodwill | 1,769,000 | 1,769,000 |
| Other intangible assets, net | 16,459,000 | 17,034,000 |
| Total assets | 68,351,000 | 67,630,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | 3,187,000 | 2,597,000 |
| Accrued expenses and deferred revenue | 2,060,000 | 1,725,000 |
| Other current liabilities | 3,185,000 | 4,367,000 |
| Accrued interest on long-term debt | 8,332,000 | 7,162,000 |
| Current portion of lease liability | 603,000 | 611,000 |
| Current portion of long-term debt, net | 30,321,000 | 30,343,000 |
| Convertible note payable related party, net | 1,376,000 | 503,000 |
| Current portion of long-term debt related party, net | 178,000 | 188,000 |
| Total current liabilities | 49,242,000 | 47,496,000 |
| Long-term debt, net | 5,272,000 | 5,727,000 |
| Long term lease liability | 5,387,000 | 5,692,000 |
| Total liabilities | 59,901,000 | 58,915,000 |
| Commitments and contingencies (Note 13) | ||
| Stockholders’ equity (deficit) | ||
| Preferred stock, $.02 par value; 47,000 shares authorized, zero shares issued and outstanding on June 30, 2026 (zero on December 31, 2025) | - | - |
| Common stock, $.02 par value; 200,000,000 shares authorized, 10,042,518 shares issued and outstanding on June 30, 2026 (9,092,518 on December 31, 2025) | 200,000 | 182,000 |
| Additional paid-in capital | 336,808,000 | 325,987,000 |
| Accumulated deficit | (337,390,000) | (327,001,000) |
| Total stockholders’ equity of the Company | (382,000) | (832,000) |
| Non-controlling interest in subsidiaries | 8,832,000 | 9,547,000 |
| Total stockholders’ equity | 8,450,000 | 8,715,000 |
| Total liabilities and stockholders’ equity | 68,351,000 | 67,630,000 |
Condensed Consolidated Statements of Cash Flows (Unaudited)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | (11,262,000) | (7,902,000) |
| Adjustments to reconcile net loss to net cash used by operating activities: | ||
| Depreciation and amortization | 1,278,000 | 1,058,000 |
| Issuance of common stock for bonus | - | 870,000 |
| Stock-based payments for professional services rendered | - | 190,000 |
| Stock-based payments to employees and directors | 1,440,000 | 4,000 |
| Loss on equity method investment | 367,000 | 5,000 |
| Unrealized loss on investments | 818,000 | 303,000 |
| Change in ROU assets | 315,000 | 330,000 |
| (Loss) gain on allowance for obsolescence of inventory | 2,000 | (21,000) |
| Provision for loan loss recoveries | - | 235,000 |
| Impairment of intangible asset | - | 600,000 |
| Amortization of debt discount | 32,000 | - |
| Loss on sale of real estate | - | 250,000 |
| Decrease (increase) in assets: | ||
| Accounts receivable | 968,000 | 380,000 |
| Inventory | 18,000 | (80,000) |
| Assets held for sale | - | (38,000) |
| Prepaid expenses and other current assets | 182,000 | 241,000 |
| Investments in trading securities | 1,984,000 | (884,000) |
| Other assets | 6,000 | (802,000) |
| Increase (decrease) in liabilities: | ||
| Accounts payable | 590,000 | (287,000) |
| Accrued expenses | 334,000 | (26,000) |
| ROU liabilities | (313,000) | (313,000) |
| Accrued interest on notes payable | 1,208,000 | 1,884,000 |
| Other liabilities | 48,000 | 3,549,000 |
| Net cash (used) provided by operating activities | (1,985,000) | (454,000) |
| Cash flows from investing activities: | ||
| Purchase of property, plant and equipment | (214,000) | (144,000) |
| Purchase of convertible bond related party | (2,450,000) | - |
| Sale of real estate | - | 9,500,000 |
| Sale of investment, related party | - | 1,500,000 |
| Issuance of new notes receivable, net origination fees | (50,000) | |
| Payments received on notes receivable | 7,000 | 163,000 |
| Net cash (used) provided by investing activities | (2,707,000) | 11,019,000 |
| Cash flows from financing activities: | ||
| Payments of long-term debt | (628,000) | (9,443,000) |
| Borrowings of long-term debt, net | 73,000 | 109,000 |
| Payment on margin loans | (1,152,000) | (3,178,000) |
| Borrowings of convertible note payable related party | 3,450,000 | - |
| Issuances of common stock, net of issuance costs | 703,000 | - |
| Net cash provided (used) by financing activities | 2,446,000 | (12,512,000) |
| Net decrease in cash | (2,246,000) | (1,947,000) |
| Cash, cash equivalents and restricted cash at beginning of period | 6,314,000 | 11,431,000 |
| Cash and cash equivalents at end of period | 4,068,000 | 9,484,000 |
Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗